At NY Genome Center, Legal Expert Presents Ethical Dilemmas in Gene Editing

At NY Genome Center, Legal Expert Presents Ethical Dilemmas in Gene Editing
Developing gene therapies for rare diseases is one thing. Creating gene-edited “designer babies” is quite another. German legal expert Timo Minssen outlined the potentially explosive ethical landmines surrounding such issues during a recent talk at the New York Genome Center. Minssen directs the Center for Advanced Studies in Biomedical Innovation Law at Denmark’s University of Copenhagen. In his June 18 talk, titled “Regulating the promises and perils of gene editing: What are our options?”,  Minssen discussed the difference between somatic cell therapy, which aims to cure disease in one specific patient, and the much more controversial germline therapy, which makes heritable genetic changes to embryos or eggs — and therefore to any offspring of that patient. “This distinction is really important, since they involve completely different ethical considerations,” said Minssen, whose area of expertise is patent law. A major breakthrough took place in 2015, when a year-ol
Subscribe or log in to read the rest of this content.